Emerging Therapies in the Management of Gastrointestinal Malignancies (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 5
Special Issue Editor
Interests: cholangiocarcinoma; biliary malignancies; primary liver cancers; metastatic liver malignancies; minimally invasive surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue "Emerging Therapies in the Management of Gastrointestinal Malignancies".
Gastrointestinal cancer is the leading cause of cancer-related deaths globally. In recent decades, the paradigm of management of gastrointestinal malignancies has shifted from conventional cytotoxic chemotherapy regimens with limited benefit to more selective and efficient, mechanism-based therapeutics. A better understanding of genomic profiling and molecular pathogenesis of tumors has resulted in the development of novel targeted therapies and precision medicine. Boosting host antitumor reaction via immunotherapy has also revolutionized the landscape for the treatment of some gastrointestinal cancers.
The management strategy of esophageal, gastric, and colorectal cancers has changed remarkably in the past decade, and there are promising developments in the treatment of cancers with a high fatality rate such as pancreas cancers and cholangiocarcinoma. In this Special Issue, we sincerely hope to gather experts to discuss the latest scientific developments in the field.
Dr. Amir A. Rahnemai Azar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- colorectal cancer
- esophageal cancer
- immunotherapy
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
